AzTrials
AzTrials

Premature InfantsNCT02943746

Targeted Protein Fortification in Extremely Low Birth Weight Preterm Infants

A study testing Standard Protein Diet and High Protein Diet in people with Premature Infants, run by Baylor College of Medicine at 1 site in United States.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record
Search all trials

Trial summary

While new innovations in the care of extremely premature infants have led to decreased morbidity and mortality, poor postnatal growth remains as a major challenge. Early growth in the postnatal period influences neurodevelopmental and growth outcomes. Read more about this study

Who is it for?
Ages 14 days and olderHealthy volunteers can take part
Conditions the study is for
Premature Infants
What is being tested?
Standard Protein Diet and High Protein Diet
Could I receive a placebo?
No, everyone receives an active treatment
How many people
118 participants
Where
1 siteUnited States
Study dates
Nov 2016to 30 Apr 2021
Phase
Interventional
Are there results?
None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

  • Ages 14 days and older
  • All sexes
  • Healthy volunteers accepted
  • Child, Adult, Older adult

Who may be able to join

  • Birth weight 500-1000 grams
  • Reasonable expectation of survival for study duration (36 weeks postmenstrual age)
  • Achieve any enteral feedings by 14 days of life
  • Born at our institution or transferred from another institution within the first 24 hours of life and receive an exclusive human milk protein diet (mother's milk supplemented with donor human milk and donor human milk derived fortifier)

Who cannot join

  • Birth weight > 1000 grams
  • Less than a reasonable expectation for survival for the study duration, enrolled in another clinical study that affects nutritional management
  • Failure to achieve enteral feeds by 14 days of life
  • Major congenital anomalies or clinically significant congenital heart disease, presence of intestinal perforation or Stage 2 NEC prior to tolerating fortified feeds
  • Early transfer to a non-study institution
  • Unable to participate in the study for any reason based on decision of study investigator

Trial locations and contacts

1 site in 1 country.

United States1 site
  • Baylor College of Medicine / Texas Children's Hospital

    Houston, Texas, 77030

Other trials in United States

About this study

Official title: Utilizing Targeted Fortification to Evaluate the Effects of a High Versus Standard Protein Diet on Linear Growth and Body Composition in Infants < 1000 g Birth Weight.

While new innovations in the care of extremely premature infants have led to decreased morbidity and mortality, poor postnatal growth remains as a major challenge. Early growth in the postnatal period influences neurodevelopmental and growth outcomes.

This proposed study will challenge current nutritional regimens for infants < 1000 g birth weight (BW) by providing an exclusive human milk based diet with a higher amount of protein based on individual caloric and protein analysis of human milk utilizing targeted fortification. The investigators will evaluate the effects of a high versus standard protein enteral diet on growth and body composition in infants < 1000 g BW.

Read more

There are no published studies evaluating the effect of an exclusive human milk protein diet on body composition in premature infants. Research has shown that infants who receive this diet achieve growth at targeted standards but body composition has not been evaluated. As an all human milk diet is well tolerated and associated with improved outcomes in the highest risk neonates, it is imperative to evaluate the benefits of a high protein exclusive human milk diet and the possible positive changes in body composition, specifically lean mass, in these infants.

Results from this proposed study will immediately influence current nutritional practices and will provide landmark information regarding targeted fortification with provision of adequate protein providing the most optimal body composition in the most fragile and vulnerable infants.

Read the detailed description

Primary Objective: To evaluate the effects of a high versus standard protein enteral diet utilizing targeted fortification on linear growth in infants < 1000 g birth weight (BW).

Hypothesis 1: Infants who receive a high protein diet will have increased length velocity at 36 weeks postmenstrual age when compared to infants who receive a standard protein diet.

Secondary Objective: To evaluate body composition by total body dual energy x-ray absorptiometry (DXA) at 36 weeks postmenstrual age in infants < 1000 g BW who received a high or standard protein enteral diet.

Hypothesis 2: Infants who received a high protein diet will have greater fat-free mass (lean mass) compared to infants who received a standard protein diet.

Protein and energy are key nutrients for growth. A low protein intake or protein to energy ratio may lead to poor linear growth and excess fat accumulation. Studies suggest that preterm infants require a high protein to energy ratio to obtain catch up growth without excessive fat accretion and that growth should focus on length gain and lean body mass.

Macronutrient analysis of donor human milk shows that mean protein values are 1.16 g/dL which is similar to term milk composition. Mother's milk and donor human milk protein content varies and is often lower than expected values. Infants may not be receiving the full amount of calories and protein needed to support growth.

The investigators plan to challenge current nutritional regimens for infants < 1000 g BW by providing an enteral diet with a higher amount of protein based on individual caloric and protein analysis of human milk also known as targeted fortification.

Study Design:

Using a prospective randomized study design, infants 500-1000 g BW receiving an exclusive human milk protein-based diet will be identified after admission to the NICU. For infants that meet inclusion criteria, the parent/guardian will be approached about the study. After informed written parental consent is obtained, infants will be randomized to receive either a high protein or standard protein diet. The standard protein diet (control group) providing 3.5-3.8 g/kg/day of protein represents our current practices. The high protein diet (intervention group) will provide 4.2-4.5 g/kg/day.

Control group (standard protein diet) versus the intervention group (high protein diet):

In the control group (standard protein diet), infants will receive a standard feeding regimen which consists of mother's own milk or donor human milk with donor human milk derived fortifier.

Once daily, a 24 hour batch of human milk will be prepared for each infant (standard practice in the milk bank). A 2.5 mL sample from the batch of human milk will be analyzed for calories (reported in kcal/oz) and protein, fat, and carbohydrate (reported in g/dL). Based on the amount of protein in the milk, fortification of feeds with donor human milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day of protein.

The intervention group (high protein diet) will receive the same standard feeding regimen with the addition of extra milk fortification to give a high protein diet. Based on the amount of protein in the milk, fortification of feeds with donor human milk derived fortifier, the number will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.

Data will be recorded for milk analysis, nutrition, and infant growth.

The diets will be continued until approximately 35 to 36 weeks postmenstrual age (PMA) at which point a DXA scan will be performed.

Infants will have 3 sets of labs for study purposes. A serum Blood Urea Nitrogen (BUN) and creatinine will be performed 2-3 days and then 1 week after goal protein is achieved. At the time of the DXA scan, a serum calcium, phosphorus, and alkaline phosphatase will be performed.

Anthropometrics: weekly weight, length, and head circumference by trained research nurse.

Human Milk Samples: A 2.5 mL sample from the batch of human milk will be analyzed using a milk analyzer. This analyzer uses a secondary method for measurements. It is calibrated with bias samples from primary methods.

Tests: DXA scan will be used to evaluate body composition and provide measures of bone mineral, lean and fat mass.

Labs: BUN; creatinine, calcium, phosphorus, and alkaline phosphatase will be obtained at the time of DXA scan to measure bone mineral status.

Sample Size:

Based on admission data from our institution, approximately 120 infants < 1000 grams are admitted to our NICU each year. A projected 50% of eligible subjects to enroll in the study. Recruitment goal is 50 subjects in each group (n=100) with an additional 10 subjects per group to account for drop out providing a total sample size of 120 infants. This would provide 89% statistical power to detect a 15% difference (hypothesized in infants who receive high protein) in length velocity at the (two sided) 5% significance level.

Study Population:

Infants will be recruited from Level 3 NICU (Texas Children's Hospital) which admits inborn premature infants and from Level 4 NICU (Texas Children's Hospital) which admits infants born at another institution. Infants from Level 4 will be recruited if they were transferred to Texas Children's Hospital within the first 24 hours of life and have received an exclusive human milk diet.

Enrolled infants will be randomized to either the (control group or intervention group). Infants are usually within a range of birth weights, gestational ages and ethnicity. Male and females are usually close to 50%. The investigators are not recruiting specific ethnicities or genders as part of the inclusion criteria.

Study Duration:

Infants will be in this study from the time of consent to 35 - 36 weeks postmenstrual age.

Being tested
Standard Protein Diet, High Protein Diet
Keywords
Standard Protein Diet, High Protein Diet, Growth, Body Composition, Extremely Low Birth Weight, Human Milk Derived Fortifier, Protein, Targeted Fortification, Human Milk Diet, Prematurity
Medical subject headings
Premature Birth

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

  • Standard Protein DietDietary supplement

    Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day.

  • High Protein DietDietary supplement

    Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day.

Study groups in NCT02943746
Study groupRoleWhat they receive
Control Group (Standard Protein Diet)Active comparatorInfants will receive a standard feeding regimen which consists of mother's own milk or donor human milk (DHM) with DHM derived fortifier. Once daily, a 24 hour batch of human milk is prepared for each infant (standard practice). A 2.5 mL sample will be analyzed for calories, protein, fat, and carbohydrates. Based on the amount of protein in the milk, fortification of feeds with donor human milk derived fortifier will be adjusted to reach an average of 3.5 to 3.8 g/kg/day of protein. Data will be recorded for milk analysis, nutrition, and infant growth. The diet will be continued until approximately 35 to 36 weeks postmenstrual age at which point a DXA scan will be performed. A serum blood urea nitrogen and creatinine as well as serum calcium, phosphorus, and alkaline phosphatase when the DXA is performed. Anthropometrics: weekly weight, length, and head circumference by trained research nurse.
Receives: Dietary Supplement: Standard Protein Diet
Intervention Group (High Protein Diet)ExperimentalThe intervention group will receive the same standard feeding regimen with the addition of extra milk fortification to give a high protein diet. Human milk will be prepared and analyzed in the same method as the control group. Based on the amount of protein in the milk, fortification of feeds with donor milk derived fortifier will be adjusted to reach an average of 4.2 to 4.5 g/kg/day. The diet will be continued until approximately 35 to 36 weeks PMA at which point a DXA scan will be performed. Infants will have 3 sets of labs. A serum blood urea nitrogen and creatinine as well as serum calcium, phosphorus, and alkaline phosphatase when the DXA is performed. Anthropometrics: weekly weight, length, and head circumference by trained research nurse.
Receives: Dietary Supplement: High Protein Diet

What is being measured

The primary outcome is the main question the study is designed to answer.

  1. Linear growth measured using an premature infant length board

    Linear growth will be measured in centimeters (cm) per week. An average weekly linear growth will be calculated for each patient over the study period.These values will be compared to published standards for age.

    Measured: Weekly until 35-36 postmenstrual age (PMA)

Secondary outcomes (1)
  1. Body composition measured by dual energy x-ray absorptiometry

    Body composition parameters including fat mass, fat-free mass, bone mineral content will be measured in each patient and the results will be compared to standards for age.

    Measured: Performed at 35-36 weeks postmenstrual age

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

  1. First posted25 Oct 2016 (estimated)
  2. Study startNov 2016
  3. Primary completion30 Apr 2021
  4. Study completion30 Apr 2021

Resources

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design
Study type
Interventional
Phase
Phase N/A
Primary purpose
Diagnosis
Allocation
Randomised
Intervention model
Parallel groups
Masking
Single blind
Who is masked
Care provider
Enrolment
118 participants (actual)
IDs, dates and publications
ClinicalTrials.gov ID
NCT02943746
Sponsor's protocol ID
H-38611
Status last verified
Jan 2026
First submitted
27 Sep 2016
Last updated
29 Jan 2026
Results posted
No
Data monitoring committee
Yes
Individual data sharing
No

Publications

  • Hair AB, Peluso AM, Hawthorne KM, Perez J, Smith DP, Khan JY, O'Donnell A, Powers RJ, Lee ML, Abrams SA. Beyond Necrotizing Enterocolitis Prevention: Improving Outcomes with an Exclusive Human Milk-Based Diet. Breastfeed Med. 2016 Mar;11(2):70-4. doi: 10.1089/bfm.2015.0134. Epub 2016 Jan 20.

    PubMed 26789484
  • Hair AB, Blanco CL, Moreira AG, Hawthorne KM, Lee ML, Rechtman DJ, Abrams SA. Randomized trial of human milk cream as a supplement to standard fortification of an exclusive human milk-based diet in infants 750-1250 g birth weight. J Pediatr. 2014 Nov;165(5):915-20. doi: 10.1016/j.jpeds.2014.07.005. Epub 2014 Aug 15.

    PubMed 25130571
  • Hair AB, Hawthorne KM, Chetta KE, Abrams SA. Human milk feeding supports adequate growth in infants </= 1250 grams birth weight. BMC Res Notes. 2013 Nov 13;6:459. doi: 10.1186/1756-0500-6-459.

    PubMed 24220185

Questions about this trial

What is this clinical trial studying?

A study testing Standard Protein Diet and High Protein Diet in people with Premature Infants, run by Baylor College of Medicine at 1 site in United States.

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 4 inclusion and 6 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 29 Jan 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in United States. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Linear growth measured using an premature infant length board (time frame: Weekly until 35-36 postmenstrual age (PMA)). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT02943746, which also lists 3 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 29 Jan 2026.

Free account

Log in to keep searching

You’ve used your 3 free searches. AzTrials is free: log in or create a free account to keep searching clinical trials and save the ones you want to follow.

Create a free accountLog in